Tag: Bezuclastinib
-
Bezuclastinib Peaks in GIST: Positive PEAK Phase 3 Results for KIT Exon 17/18 Mutants
New Phase 3 data positions Bezuclastinib as a potential new standard for KIT Exon 17/18 mutant GIST In a pivotal development for patients with advanced gastrointestinal stromal tumors (GISTs), Bezuclastinib demonstrated positive outcomes in the PEAK Phase 3 study focusing on KIT exon 17/18 mutant disease. GISTs are driven by complex mutations in the KIT…
-
Bezuclastinib Achieves Positive PEAK Phase 3 Results in Advanced GIST: A Potential New Standard for KIT Exon 17/18 Mutant Disease
Bezuclastinib Makes a Major Leap in KIT Exon 17/18 Mutant GIST Recent PEAK Phase 3 results are positioning Bezuclinib as a potentially practice-changing therapy for patients with advanced gastrointestinal stromal tumors (GIST) driven by KIT Exon 17/18 mutations. These mutations have long been associated with primary resistance to first-line therapies and later-line inhibitors, making the…
-
Bezuclastinib PEAK Phase 3: A Potential New Standard for KIT Exon 17/18 GIST
Bezuclastinib Hits Positive PEAK Phase 3 Results in Advanced GIST Gastrointestinal stromal tumors (GIST) have long been driven by KIT mutations, with targeted therapies reshaping patient outcomes over the past two decades. The emergence of resistance, particularly in those with KIT Exon 17 and Exon 18 mutations, has remained a persistent challenge. Bezuclastinib’s latest PEAK…